This company has been marked as potentially delisted and may not be actively trading. NASDAQ:MDCO Medicines (MDCO) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Medicines Stock (NASDAQ:MDCO) 30 days 90 days 365 days Advanced Chart Get Medicines alerts:Sign Up Key Stats Today's Range$84.90▼$84.9050-Day Range$84.90▼$84.9052-Week Range$17.81▼$84.98VolumeN/AAverage Volume9.55 million shsMarket Capitalization$6.77 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview The Medicines Company, a biopharmaceutical company, focuses on developing therapeutics for the treatment of therosclerotic cardiovascular disease. The company is developing Inclisiran, an investigational RNA interference therapeutic that inhibits production of proprotein convertase subtilisin/kexin type 9, which controls LDL-cholesterol levels. It has collaboration agreement with Alnylam Pharmaceuticals, Inc. The Medicines Company was founded in 1996 and is headquartered in Parsippany, New Jersey. Read More Receive MDCO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medicines and its competitors with MarketBeat's FREE daily newsletter. Email Address MDCO Stock News HeadlinesValneva’s Chikungunya Vaccine Restriction Lifted by EMAJuly 11 at 2:45 PM | tipranks.comBeOne Medicines (ONC) Gains EU Approval for Tevimbra in Cancer TherapyJuly 10 at 12:22 PM | gurufocus.comIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as July 23rd.July 13 at 2:00 AM | Brownstone Research (Ad)Kingworld Medicines Clarifies 2025 Share Award Scheme DetailsJuly 10 at 9:36 AM | tipranks.comBeOne Medicines (ONC) Gains EU Approval for TEVIMBRA in Nasopharyngeal Carcinoma | ONC Stock NewsJuly 10 at 6:57 AM | gurufocus.comRevolution Medicines: Strategic Growth and Financial Stability Drive Buy RatingJuly 10 at 5:33 AM | tipranks.comBiocytogen Enters into Antibody Licensing Agreement with BeOne Medicines to Accelerate Innovative Drug DevelopmentJuly 9, 2025 | financialpost.comFBiocytogen Enters into Antibody Licensing Agreement with BeOne Medicines to Accelerate Innovative Drug DevelopmentJuly 9, 2025 | financialpost.comFSee More Headlines MDCO Stock Analysis - Frequently Asked Questions How were Medicines' earnings last quarter? The Medicines Company (NASDAQ:MDCO) announced its quarterly earnings data on Wednesday, October, 30th. The company reported ($0.92) earnings per share for the quarter, missing analysts' consensus estimates of ($0.80) by $0.12. What other stocks do shareholders of Medicines own? Based on aggregate information from My MarketBeat watchlists, some other companies that Medicines investors own include Bristol Myers Squibb (BMY), NVIDIA (NVDA), Gilead Sciences (GILD), Micron Technology (MU), AbbVie (ABBV), Alibaba Group (BABA) and Salesforce (CRM). Company Calendar Last Earnings10/30/2019Today7/13/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:MDCO CIK1113481 Webwww.themedicinescompany.com Phone973-290-6000FaxN/AEmployees62Year FoundedN/AProfitability EPS (Trailing Twelve Months)($2.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$123.16 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-25.70% Debt Debt-to-Equity Ratio21.45 Current Ratio0.77 Quick Ratio0.77 Sales & Book Value Annual Sales$6.14 million Price / Sales1,102.36 Cash FlowN/A Price / Cash FlowN/A Book Value($0.30) per share Price / Book-283.00Miscellaneous Outstanding Shares79,723,000Free FloatN/AMarket Cap$6.77 billion OptionableOptionable Beta1.10 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:MDCO) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding The Medicines Company Please log in to your account or sign up in order to add this asset to your watchlist. Share Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
